While no anti-human IL-10 antibody has been approved for cancer treatment, the production of IL-17A and adenosine could be targeted in tumors that are highly infiltrated by pro-tumor γδ T cells, such as breast and colorectal cancer. The gene discussed is IL17A; the disease is neoplasm.